SecBot SecBot
SECBOTREPLAY Home › Report › VRTX

VRTX · Vertex reported Q3 2026 total revenue of $3.44 billion, a 12% increase…

VERTEX PHARMACEUTICALS INC / MA · 8-K filed Nov 2, 2026 at 16:05 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 2, 2026 at 16:05 ET

Vertex reported Q3 2026 total revenue of $3.44 billion, a 12% increase YoY, and raised full-year 2026 revenue guidance to $13.15-$13.25 billion. The quarter included the close of the $10B Crinetics acquisition and highlighted strong growth from non-CF products CASGEVY ($99M, +486% YoY) and JOURNAVX ($58M, +197% YoY), with a key near-term catalyst being the November 30 PDUFA date for povetacicept in IgAN.

  • Q3 2026 total revenue of $3.44 billion, up 12% YoY from $3.08 billion
  • Full-year 2026 revenue guidance raised to $13.15-$13.25 billion from $13.1-$13.2 billion
  • GAAP net income of $654 million, down from $1.08 billion YoY due to Crinetics acquisition costs
  • CASGEVY revenue of $99 million, up 486% YoY and 30% QoQ

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access